术后眼内炎致病菌与视力结局的关系
这项回顾性干预性病例系列纳入2012至2022年四所大学附属三级中心240例术后急性眼内炎成人患者,其中208例随访资料完整可供比较分析。培养阳性病例中,非表面共生菌(如链球菌、肠球菌)感染者最终视力、需第三次干预率、眼球萎缩率及眼球摘除/内容物剜出率均显著劣于凝固酶阴性葡萄球菌感染者,多变量回归显示其与较差视力结局独立相关。
要点
- 非表面共生菌感染者最终视力显著差于凝固酶阴性葡萄球菌感染者(平均logMAR 2.14 vs 0.77,P < .0001)。
- 非表面共生菌组第三次干预率27.5% vs 10.1%(P = .017),眼球萎缩率15.4% vs 1.1%(P = .0032)。
- 多数患者初始接受玻璃体内注射治疗(92.1%),初始玻璃体切除术不常见且未与更好结局显著相关。
核心结论
- 致病力强的非表面共生菌(如链球菌、肠球菌)感染与术后眼内炎显著更差的结局相关,且独立于就诊视力和治疗延迟。
- 这些发现支持转向基于病原菌的管理,并强调及时鉴定术后急性眼内炎中致病力强病原菌的必要性。
研究设计与样本
- 回顾性、干预性病例系列;2012至2022年四所大学附属三级中心共240例术后急性眼内炎成人患者,其中208例随访资料完整可供比较分析。
- 按病原体分为表面共生菌(凝固酶阴性葡萄球菌)与非表面共生菌(如链球菌、肠球菌)作为致病力替代指标;采用Fisher精确检验及校正年龄、性别、合并症和注射后眼内炎治疗方式的多变量回归模型比较视力结局与并发症率。
主要发现
- 培养阳性病例中,非表面共生菌感染者最终视力显著差于凝固酶阴性葡萄球菌感染者(平均logMAR 2.14 vs 0.77,P < .0001)。
- 非表面共生菌组第三次干预率27.5% vs 凝固酶阴性葡萄球菌组10.1%(P = .017);眼球萎缩率15.4% vs 1.1%(P = .0032);眼球摘除/内容物剜出率12.8% vs 0%(P = .0022)。
- 注射后眼内炎多变量回归中,致病力强的非表面共生菌仍与较差视力结局独立相关(P = .0005)。
- 无论是否将培养阴性病例纳入非致病力组,并发症模式均一致。
- 多数患者初始接受玻璃体内注射治疗(92.1%);初始玻璃体切除术不常见,且施行时未与更好结局显著相关。
关键数值与推荐
- 非表面共生菌组最终视力平均logMAR 2.14 vs 凝固酶阴性葡萄球菌组0.77(P < .0001)。
- 非表面共生菌组第三次干预率27.5% vs 凝固酶阴性葡萄球菌组10.1%(P = .017)。
- 非表面共生菌组眼球萎缩率15.4% vs 凝固酶阴性葡萄球菌组1.1%(P = .0032)。
- 非表面共生菌组眼球摘除/内容物剜出率12.8% vs 凝固酶阴性葡萄球菌组0%(P = .0022)。
- 注射后眼内炎多变量回归中,致病力强的非表面共生菌与较差视力结局独立相关(P = .0005)。
临床怎么用
- 作者认为这些发现支持转向基于病原菌的管理,并强调及时鉴定术后急性眼内炎中致病力强病原菌的必要性。
- 多数患者初始治疗为玻璃体内注射(92.1%);初始玻璃体切除术不常见,且施行时未与更好结局显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the anatomic and functional outcomes of a large, multicenter series of postprocedure acute endophthalmitis, stratified by pathogen virulence. DESIGN: Retrospective, interventional case series. PARTICIPANTS: Two hundred forty adult patients diagnosed with postprocedural acute endophthalmitis from 2012 to 2022 at four tertiary, university-based care centers. Of these, 208 patients had adequate follow-up data for comparative analyses. METHODS: Medical records were reviewed for demographics, microbiology, treatment, and visual outcomes of patients that developed endophthalmitis following any intraocular procedure. Organisms were categorized into surface commensals (coagulase-negative Staphylococcus sp.) and nonsurface commensals (eg, Streptococcus, Enterococcus sp.) as a proxy for virulence. Visual acuity (VA) outcomes and complication rates were compared across groups using Fisher's exact test and regression models adjusting for age, sex (male or female), comorbidities, and treatment modality for postinjection endophthalmitis. MAIN OUTCOME MEASURES: Final VA, number of interventions, and rates of vision-threatening complications, including phthisis, retinal detachment, enucleation/evisceration. RESULTS: Among culture-positive cases, patients infected with nonsurface commensal organisms had significantly worse final VA than those with coagulase-negative Staphylococcus (mean logMAR 2.14 vs 0.77, P < .0001), as well as higher rates of third interventions (27.5% vs 10.1%, P = .017), phthisis (15.4% vs 1.1%, P = .0032), and enucleation/evisceration (12.8% vs 0%, P = .0022). In multivariable regression of postinjection endophthalmitis, virulent, nonsurface commensal organisms remained independently associated with poorer visual outcomes (P = .0005). Complication patterns were consistent whether culture-negative cases were included or not in the nonvirulent group. Most patients were initially treated with intravitreal injections (92.1%). An initial vitrectomy was uncommon and not significantly associated with better outcomes when performed. CONCLUSIONS: Infections with virulent, nonsurface commensal organisms such as Streptococcus and Enterococcus are associated with significantly worse outcomes in postprocedure endophthalmitis, independent of presenting vision or treatment delay. These findings support a shift toward pathogen-informed management and underscore the need for timely identification of virulent organisms in postprocedural acute endophthalmitis.
引用
- Ather M, Lyden E, Zhan Y, et al. Pathogen-Associated Visual Outcomes Following Postprocedure Endophthalmitis. Am J Ophthalmol. 2025. PMID: 41317830. doi:10.1016/j.ajo.2025.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。